Pathogen reduction of blood components during outbreaks of infectious diseases in the European Union: an expert opinion from the European Centre for Disease Prevention and Control consultation meeting.
Dragoslav Domanović(European Centre for Disease Prevention and Control), Paolo Rebulla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ines Ushiro‐Lumb(NHS Blood and Transplant), Markus B. Funk(Paul Ehrlich Institut), Pierre Gallian(Établissement Français du Sang), Simonetta Pupella, Claudio Velati, Miguel Ángel Vesga(Institute for Transfusion Medicine), Jørgen Georgsen(Odense University Hospital), S Brusin(European Centre for Disease Prevention and Control), Constantina Politis(National Public Health Organization), Giuseppe Marano, Teresa Jimenéz‐Marco(Universitat de les Illes Balears), Karmin Saadat(Austrian Agency for Health and Food Safety), Imad Sandid, G Rautmann, Stefania Vaglio, Nicole Verdun(Center for Biologics Evaluation and Research), Veerle Compernolle(Vlaams Instituut voor Biotechnologie), Polonca Mali(Blood Transfusion Centre of Slovenia), Folke Knutson(Uppsala University), Mart P. Janssen(Sanquin), Ana Paula Sousa(Centro Hospitalar Lisboa Norte), Yuyun Maryuningsih(World Health Organization), Giancarlo M Liumbruno, Christoph Niederhauser(Swiss Red Cross)
Cited by 30
Related Papers
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
|Nature Medicine|2001|1.7k
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19
|New England Journal of Medicine|2021|553
Early safety indicators of COVID-19 convalescent plasma in 5000 patients
|Journal of Clinical Investigation|2020|485
Safety Update
|Mayo Clinic Proceedings|2020|432
Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2024|257